P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES
Jennifer Woyach,
Ian W. Flinn,
Farrukh Awan,
Herbert Eradat,
Danielle M. Brander,
Michael Tees,
Sameer Parikh,
Tycel Phillips,
Razi Ghori,
Ima Paydar,
Mohammed Z. H. Farooqui,
John C. Byrd,
Deborah Stephens
Affiliations
Jennifer Woyach
1 The Ohio State University, Columbus, United States
Ian W. Flinn
2 Sarah Cannon Research Institute, Nashville, United States
Farrukh Awan
3 University of Texas Southwestern Medical Center, Dallas, United States
Herbert Eradat
4 David Geffen School of Medicine at UCLA, Los Angeles, United States
Danielle M. Brander
5 Duke University, Duke PDC, Durham, United States
Michael Tees
6 Colorado Blood Cancer Institute, Denver, United States
Sameer Parikh
7 Mayo Clinic, Rochester, United States
Tycel Phillips
8 University of Michigan Rogel Cancer Center, Ann Arbor, United States
Razi Ghori
9 Merck & Co., Inc., Rahway, United States
Ima Paydar
9 Merck & Co., Inc., Rahway, United States
Mohammed Z. H. Farooqui
9 Merck & Co., Inc., Rahway, United States
John C. Byrd
10 University of Cincinnati College of Medicine, Cincinnati, United States
Deborah Stephens
11 University of Utah Huntsman Cancer Institute, Salt Lake City, United States
